Skip to content

Effects of Targeted injection of Morphine into Stellate ganglion on Myocardial Reperfusion Injury and Long-term Prognosis in Patients with Acute myocardial Infarction

Effects of Targeted injection of Morphine into Stellate ganglion on Myocardial Reperfusion Injury and Long-term Prognosis in Patients with Acute myocardial Infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078233
Enrollment
Unknown
Registered
2023-12-01
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Morphine Injection Group:The left stellate ganglion was given an injection of morphine (10 mg, 10 ml) under ultrasound guidance within 30 minutes before coronary artery recanalization.
Normal Saline Injection Group:Before coronary vascular recanalization, the left stellate ganglion was given an equal amount of normal saline (10 ml) under ultrasound guidance.

Sponsors

The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients with acute myocardial infarction who were to undergo coronary revascularization; 2) Age >18 years old, gender is not limited; 3) Body mass index (BMI) 18.5~30 kg/m2; 4) Obtain informed consent from patients and their families.

Exclusion criteria

Exclusion criteria: 1) A history of opioid addiction; 2) Patients with cardiomyopathy of unknown cause; 3) Patients with diabetes and obesity; 4) Severe mental illness can not cooperate; 5) Complicated with serious systemic diseases such as blood diseases, liver and kidney insufficiency, etc.

Design outcomes

Primary

MeasureTime frame
cardiac troponin I;All-cause mortality at 1 year after surgery;

Secondary

MeasureTime frame
Echocardiography;Stroke;Postoperative adverse event;Electrocardiogram;B Type Natriuretic Peptide;New Atrial Fibrillation;

Countries

China

Contacts

Public ContactZhang Ye

The Second Affiliated Hospital of Anhui Medical University, Hefei, China

zhengye_hassan@sina.com+86 139 6676 8081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026